Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (1892)	1/24/2002 4:10:49 PM
From: Cacaito	Read Replies (1) \| Respond to of 2515

Someone oppinion: "Mike Krensavage, a drug analyst for Raymond James & Associates, said Dolan no doubt plans to get some of Bristol- Myers' money back from ImClone and might file suit against the firm to get it. ``The relationship between Bristol-Myers and ImClone has deteriorated. So either through the court system or through a revised marketing agreement, Bristol-Myers will probably try to get some money back for its shareholders,'' Krensavage said."

To: aknahow who wrote (1892)	1/24/2002 4:12:19 PM
From: cyberman	Read Replies (1) \| Respond to of 2515

Has anyone on this board thought or discussed Erbitux' delay/possible failure and its possible effects on the competition? Remember Erbitux isn't the only cancer product in development. How about AstraZeneca's Iressa and OSI's Tarceva? Are these product candidates in a better or worse position as a result of this fiasco? Does anyone know the differences in the Tarceva trials as compared to the Erbitux? Or the Iressa trials for that matter? Just curious if the EGFR-receptor arena has been covered already...Thanks